Exelixis, Inc.
(NASDAQ:EXEL)|
2.78 -0.31 (-10.03%) Dec 01 - Close |
|
|
|
After-Hours 2.80 +0.02 (0.72%) Mon, 1 Dec 2008 6:50 PM
- Compare EXEL with:
- View: Line | Candlestick
Company Profile
Exelixis, Inc.
170 Harbor Way
South San Francisco, CA 94083
United States - Map
Phone: (650) 837-7000
Fax: (650) 837-8205
Website: www.exelixis.com
State of incorporation: Delaware
CEO: Dr. George A. Scangos, Ph.D.
Employees: 735
Sector: Healthcare
Industry Group: Drugs
Industry: Biotechnology
Leader in the field of model system genetics
The Company is engaged in the discovery and development of therapies for the treatment of cancer and other serious diseases.
Recent news for EXEL
-
Motley Fool - Nov 25 at 2:45 ET
-
Exelixis Has Friends With Cash
Motley Fool - Nov 25 at 2:38 ET
-
Exelixis wins $20 million in Bristol-Myers Squibb deal
bizjournals.com - Nov 25 at 8:05 ET
-
Investor's Business Daily - Nov 24 at 7:04 ET
-
Exelixis 4th Annual R&D Day Call scheduled for Fri, Dec 12
CCBN - Nov 24 at 5:10 ET
-
Exelixis Announces December 12 Webcast of Its Fourth Annual R&D Day
Business Wire - Nov 24 at 4:05 ET
-
5-Star Stocks Poised to Pop: Exelixis
Motley Fool - Nov 24 at 10:53 ET
-
How Lucrative Is Bristol-Myers Collaboration With Exelixis?
Seeking Alpha - Nov 24 at 10:22 ET
-
Exelixis gets $20 million in Bristol-Myers deal
AP - Nov 24 at 7:25 ET
-
UPDATE - Exelixis to co-develop cancer therapy with Bristol
Reuters - Nov 24 at 6:49 ET
